Cengiz Goekeri

Jan 10, 2024 | virologyj.biomedcentral.com | Hartmut Kuhn |Maximilian Schreiner |Werner Wenzel |Cengiz Goekeri |Lorenz Scheit |Dominic Rauschning | +7 more

The present study is a post-hoc analysis of a previously published prospective observational study with hospitalized COVID-19 patients (Frontiers in Microbiology: “Serum interleukin-6, procalcitonin, and C-reactive protein at hospital admission can identify patients at low risk for severe COVID-19 progression” [27]). We have added a second cohort of ambulatory mild affected COVID-19 participants (outpatients).